vs
AVALON HOLDINGS CORP（AWX）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是AVALON HOLDINGS CORP的1.4倍（$30.3M vs $21.5M），AVALON HOLDINGS CORP净利率更高（-1.7% vs -221.3%，领先219.7%），REGENXBIO Inc.同比增速更快（43.0% vs 21.7%），AVALON HOLDINGS CORP自由现金流更多（$-166.0K vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 6.7%）
阿瓦隆山游戏公司是一家专业出版兵棋推演与策略桌游的游戏企业，业务也涵盖微缩兵棋规则、角色扮演游戏及体育模拟类游戏的出版。该公司隶属于孩之宝，在孩之宝旗下的游戏事业部开展运营。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
AWX vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.4倍
$21.5M
营收增速更快
RGNX
高出21.3%
21.7%
净利率更高
AWX
高出219.7%
-221.3%
自由现金流更多
AWX
多$52.6M
$-52.8M
两年增速更快
RGNX
近两年复合增速
6.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $21.5M | $30.3M |
| 净利润 | $-356.0K | $-67.1M |
| 毛利率 | 17.1% | — |
| 营业利润率 | 0.4% | -190.0% |
| 净利率 | -1.7% | -221.3% |
| 营收同比 | 21.7% | 43.0% |
| 净利润同比 | 28.4% | -31.2% |
| 每股收益（稀释后） | — | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AWXRGNX
| Q4 25 | $21.5M | $30.3M | ||
| Q3 25 | $25.7M | $29.7M | ||
| Q2 25 | $20.3M | $21.4M | ||
| Q1 25 | $16.1M | $89.0M | ||
| Q4 24 | $17.6M | $21.2M | ||
| Q3 24 | $24.2M | $24.2M | ||
| Q2 24 | $23.1M | $22.3M | ||
| Q1 24 | $18.9M | $15.6M |
净利润AWXRGNX
| Q4 25 | $-356.0K | $-67.1M | ||
| Q3 25 | $1.9M | $-61.9M | ||
| Q2 25 | $274.0K | $-70.9M | ||
| Q1 25 | $-1.5M | $6.1M | ||
| Q4 24 | $-497.0K | $-51.2M | ||
| Q3 24 | $1.8M | $-59.6M | ||
| Q2 24 | $954.0K | $-53.0M | ||
| Q1 24 | $-979.0K | $-63.3M |
毛利率AWXRGNX
| Q4 25 | 17.1% | — | ||
| Q3 25 | 23.7% | — | ||
| Q2 25 | 20.6% | — | ||
| Q1 25 | 14.8% | — | ||
| Q4 24 | 17.5% | 70.2% | ||
| Q3 24 | 24.6% | 48.8% | ||
| Q2 24 | 22.1% | 52.5% | ||
| Q1 24 | 16.2% | 72.6% |
营业利润率AWXRGNX
| Q4 25 | 0.4% | -190.0% | ||
| Q3 25 | 9.1% | -176.3% | ||
| Q2 25 | 3.7% | -296.3% | ||
| Q1 25 | -7.2% | 13.6% | ||
| Q4 24 | -0.8% | -242.1% | ||
| Q3 24 | 9.4% | -256.6% | ||
| Q2 24 | 6.3% | -251.3% | ||
| Q1 24 | -2.7% | -408.8% |
净利率AWXRGNX
| Q4 25 | -1.7% | -221.3% | ||
| Q3 25 | 7.4% | -208.3% | ||
| Q2 25 | 1.4% | -331.8% | ||
| Q1 25 | -9.3% | 6.8% | ||
| Q4 24 | -2.8% | -241.3% | ||
| Q3 24 | 7.6% | -246.3% | ||
| Q2 24 | 4.1% | -237.7% | ||
| Q1 24 | -5.2% | -405.4% |
每股收益（稀释后）AWXRGNX
| Q4 25 | — | $-1.30 | ||
| Q3 25 | — | $-1.20 | ||
| Q2 25 | — | $-1.38 | ||
| Q1 25 | — | $0.12 | ||
| Q4 24 | — | $-0.99 | ||
| Q3 24 | — | $-1.17 | ||
| Q2 24 | — | $-1.05 | ||
| Q1 24 | — | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $4.1M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $38.4M | $102.7M |
| 总资产 | $87.4M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AWXRGNX
| Q4 25 | $4.1M | $230.1M | ||
| Q3 25 | $4.6M | $274.2M | ||
| Q2 25 | $3.7M | $323.3M | ||
| Q1 25 | $1.3M | $267.9M | ||
| Q4 24 | $2.8M | $234.7M | ||
| Q3 24 | $3.9M | $255.5M | ||
| Q2 24 | $3.8M | $290.4M | ||
| Q1 24 | $1.2M | $338.7M |
股东权益AWXRGNX
| Q4 25 | $38.4M | $102.7M | ||
| Q3 25 | $38.7M | $161.5M | ||
| Q2 25 | $36.8M | $213.7M | ||
| Q1 25 | $36.5M | $274.2M | ||
| Q4 24 | $38.0M | $259.7M | ||
| Q3 24 | $38.5M | $301.4M | ||
| Q2 24 | $36.7M | $348.3M | ||
| Q1 24 | $35.7M | $390.7M |
总资产AWXRGNX
| Q4 25 | $87.4M | $453.0M | ||
| Q3 25 | $90.7M | $525.2M | ||
| Q2 25 | $88.1M | $581.0M | ||
| Q1 25 | $87.6M | $490.9M | ||
| Q4 24 | $86.2M | $466.0M | ||
| Q3 24 | $89.1M | $519.1M | ||
| Q2 24 | $91.7M | $569.4M | ||
| Q1 24 | $90.6M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $278.0K | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-166.0K | $-52.8M |
| 自由现金流率自由现金流/营收 | -0.8% | -174.0% |
| 资本支出强度资本支出/营收 | 2.1% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $2.1M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流AWXRGNX
| Q4 25 | $278.0K | $-52.3M | ||
| Q3 25 | $1.5M | $-56.0M | ||
| Q2 25 | $3.0M | $-49.3M | ||
| Q1 25 | $-982.0K | $33.6M | ||
| Q4 24 | $-579.0K | $-31.6M | ||
| Q3 24 | $342.0K | $-40.5M | ||
| Q2 24 | $3.2M | $-45.5M | ||
| Q1 24 | $411.0K | $-55.5M |
自由现金流AWXRGNX
| Q4 25 | $-166.0K | $-52.8M | ||
| Q3 25 | $852.0K | $-56.5M | ||
| Q2 25 | $2.7M | $-49.7M | ||
| Q1 25 | $-1.4M | $32.6M | ||
| Q4 24 | $-1.1M | $-32.7M | ||
| Q3 24 | $-660.0K | $-40.9M | ||
| Q2 24 | $2.9M | $-46.0M | ||
| Q1 24 | $56.0K | $-56.0M |
自由现金流率AWXRGNX
| Q4 25 | -0.8% | -174.0% | ||
| Q3 25 | 3.3% | -189.9% | ||
| Q2 25 | 13.5% | -232.8% | ||
| Q1 25 | -8.5% | 36.6% | ||
| Q4 24 | -6.4% | -154.2% | ||
| Q3 24 | -2.7% | -168.9% | ||
| Q2 24 | 12.4% | -206.2% | ||
| Q1 24 | 0.3% | -358.5% |
资本支出强度AWXRGNX
| Q4 25 | 2.1% | 1.7% | ||
| Q3 25 | 2.3% | 1.7% | ||
| Q2 25 | 1.4% | 1.8% | ||
| Q1 25 | 2.4% | 1.2% | ||
| Q4 24 | 3.1% | 5.1% | ||
| Q3 24 | 4.1% | 1.3% | ||
| Q2 24 | 1.5% | 2.1% | ||
| Q1 24 | 1.9% | 3.6% |
现金转化率AWXRGNX
| Q4 25 | — | — | ||
| Q3 25 | 0.76× | — | ||
| Q2 25 | 11.07× | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.19× | — | ||
| Q2 24 | 3.35× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AWX
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
